PainReform, a Phase 2 Israeli biotech developing therapies for post-operative pain relief, raised $20 million by offering 2.5 million units at $8, the low end of the range of $8 to $10. Each unit consists of one share of common stock and one warrant, exercisable...read more
PainReform, a Phase 2 Israeli biotech developing therapies for post-operative pain relief, revised the terms for its upcoming IPO on Monday. The Herzliya, Israel-based company now plans to raise $23 million by offering 2.6 million units at a price range of...read more
Two IPOs and two SPACs are scheduled to go public in the week ahead. Chinese EV maker Xpeng (XPEV) is leading summer's last wave with a billion-dollar deal. Xpeng (XPEV) plans to raise $1.0 billion at an $8.8 billion market cap....read more
PainReform, a Phase 2 Israeli biotech developing therapies for post-operative pain relief, announced terms for its IPO on Wednesday. The Herzliya, Israel-based company plans to raise $23 million by offering 2.6 million shares at a price range of $8 to $10....read more
Israeli pain relief biotech PainReform prices US IPO at $8 low end
PainReform, a Phase 2 Israeli biotech developing therapies for post-operative pain relief, raised $20 million by offering 2.5 million units at $8, the low end of the range of $8 to $10. Each unit consists of one share of common stock and one warrant, exercisable...read more
Israeli pain relief biotech PainReform revises terms for $23 million US IPO, now offering units
PainReform, a Phase 2 Israeli biotech developing therapies for post-operative pain relief, revised the terms for its upcoming IPO on Monday. The Herzliya, Israel-based company now plans to raise $23 million by offering 2.6 million units at a price range of...read more
US IPO Week Ahead: Chinese EV's billion-dollar deal closes out summer in a 2 IPO week
Two IPOs and two SPACs are scheduled to go public in the week ahead. Chinese EV maker Xpeng (XPEV) is leading summer's last wave with a billion-dollar deal. Xpeng (XPEV) plans to raise $1.0 billion at an $8.8 billion market cap....read more
Israeli pain relief biotech PainReform sets terms for $23 million IPO
PainReform, a Phase 2 Israeli biotech developing therapies for post-operative pain relief, announced terms for its IPO on Wednesday. The Herzliya, Israel-based company plans to raise $23 million by offering 2.6 million shares at a price range of $8 to $10....read more